DOCSLIB.ORG

Side Effects of Antidepressants: an Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Side Effects of Antidepressants: an Overview CURRENT DRUG THERAPY ELIAS A. KHAWAM, MD GEORGIA LAURENCIC, MD DONALD A. MALONE JR., MD Louis Stokes Cleveland VA Medical Center; Department of Psychiatry and Psychology, Head, Section of Adult Primary Services, Senior Instructor, Department of Psychiatry, Cleveland Clinic Department of Psychiatry and Psychology, Case Western Reserve University Cleveland Clinic Side effects of antidepressants: An overview ■ ABSTRACT URRENT ANTIDEPRESSANT DRUGS are C effective and generally well tolerated, but Adverse effects of antidepressant drugs can decrease noncompliance remains worrisome. Up to 70% compliance and delay recovery. It is therefore crucial to of patients taking antidepressants are noncom- consider potential side effects when choosing an pliant,1,2 as a result of either missed doses or antidepressant. Although there is no perfect premature discontinuation. According to Lin antidepressant that works quickly and is completely free et al,1 28% of patients stopped taking antide- of adverse reactions, newer antidepressants are safer, pressants in the first month of treatment, and better tolerated, and associated with a lower rate of 44% discontinued by the third month. Several noncompliance. reasons were identified for premature discon- tinuation, with side effects the most common. ■ KEY POINTS Dropout rates in studies of tricyclic antidepres- sants varied from 7% to 44%; in studies of sero- Although side effects can be idiosyncratic, most can be tonin reuptake inhibitors, the dropout rates explained by the drug’s mechanism of action. were 7% to 23%.3,4 Physicians should educate and reassure Most antidepressant side effects subside within the first their patients about potential side effects. Benign and transient side effects are more few days to weeks of therapy. common than dangerous or irreversible effects, especially with the newer antidepres- Sexual dysfunction is a side effect of all serotonin sants. This knowledge can help in reducing reuptake inhibitors, venlafaxine, and duloxetine. the rate of medication discontinuation, which Bupropion and nefazodone have the lowest risk for is important because even after a medication sexual side effects. has produced the desired benefit, it needs to be continued to prevent relapses. The risk of suicide may be increased during the first This article will focus on the adverse month or so of antidepressant therapy; physicians, effects of antidepressants, with the goal of patients, and family members should be vigilant for signs helping physicians to recognize and under- of suicidal thoughts and behavior. stand them, so that patients can undergo effective treatment. In elderly patients, serotonin reuptake inhibitors seem to ■ SIDE EFFECTS ARE USUALLY PREDICTABLE be safer and better tolerated than tricyclic antidepressants. The choice should be made on the basis Medications are the mainstay of treatment of of side effect profile and drug interactions. moderate to severe depression, often com- bined with psychotherapy.5 In addition, anti- depressants are used to treat other psychiatric PATIENT INFORMATION illnesses and even medical illnesses (TABLE 1). If you need an antidepressant, page 363 Although some side effects of antidepres- CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 • NUMBER 4 APRIL 2006 351 Downloaded from www.ccjm.org on September 23, 2021. For personal use only. All other uses require permission. ANTIDEPRESSANTS KHAWAM, LAURENCIC, AND MALONE TABLE 1 Mechanism of serotonin reuptake inhibitors Serotonin reuptake inhibitors selectively Other indications for antidepressant drugs block serotonin reuptake at the presynaptic Anxiety disorders: phobic disorders, panic disorder, nerve terminal. obsessive-compulsive disorder, generalized anxiety disorder, Citalopram and escitalopram have the post-traumatic stress disorder most selective effect on serotonin reuptake, with little inhibitory effect on norepinephrine Attention deficit and disruptive behavior disorders and dopamine reuptake and a low affinity for Eating disorders: anorexia and bulimia alpha 1 adrenergic receptors, muscarinic Gastrointestinal disorders: irritable bowel syndrome cholinergic receptors, and histamine H1 receptors.11,12 Genitourinary disorders: enuresis Other serotonin reuptake inhibitors have Pain syndromes: migraine headache, other chronic pain conditions similar profiles, except that paroxetine has some anticholinergic properties, fluoxetine Psychotic disorders: schizoaffective disorder weakly inhibits norepinephrine reuptake, and Sleep disorders: insomnia, night terrors, sleep apnea, narcolepsy, sertraline weakly inhibits norepinephrine and functional enuresis dopamine reuptake.7–9,11 Pharmacokinetics of serotonin reuptake inhibitors sant drugs are idiosyncratic, most can be Serotonin reuptake inhibitors differ in their explained by their effects at the synaptic level pharmacokinetics. Fluoxetine has the longest (TABLE 2).6,7 Antidepressants typically block half-life, and its active metabolite (norfluoxe- the reuptake of certain neurotransmitters tine) has a half-life of 7 to 15 days.11 Paroxetine (norepinephrine, serotonin, and dopamine) and fluvoxamine have relatively short half-lives back into the nerve ending and block some of (21 and 15 hours, respectively). the other neurotransmitter receptors.7–10 The All serotonin reuptake inhibitors are Serotonin most clinically relevant receptor blockade metabolized in the liver by the cytochrome P- reuptake occurs at muscarinic (acetylcholine), hista- 450 system.11 Because they competitively minic (H1), alpha-1 adrenergic, dopaminer- inhibit these hepatic enzymes, serotonin reup- inhibitors are gic (D2), and possibly serotonergic (5- take inhibitors can increase the levels of other metabolized HT2A) receptors. medications metabolized by these enzymes, Side effects are not always a disadvantage. possibly leading to toxic effects. The greater by the P-450 For example, a patient with insomnia may the P-450 inhibition, the greater the possibili- system benefit from a sedating antidepressant given at ty of drug interactions. For example, giving bedtime. desipramine (a tricyclic antidepressant) with a serotonin reuptake inhibitor such as fluoxetine ■ SEROTONIN REUPTAKE INHIBITORS can lead to as much as a fourfold increase in the plasma level of desipramine, which could Serotonin reuptake inhibitors have replaced lead to increased anticholinergic effects, seda- the tricyclic antidepressants as the first-line tion, seizures, and cardiotoxicity. Fluoxetine treatment for depression and now account for might interact with warfarin, with the possibil- most prescriptions for antidepressants in the ity of an increased anticoagulant effect and an United States. Fluoxetine (Prozac) was intro- increased risk of bleeding. duced in 1988 and was followed by sertraline (Zoloft), paroxetine (Paxil), fluvoxamine Side effects (Luvox), citalopram (Celexa), and escitalo- of serotonin reuptake inhibitors pram (Lexapro). All but fluvoxamine are Serotonin reuptake inhibitors are generally approved by the US Food and Drug well tolerated. However, approximately 15% Administration (FDA) for treating depres- of patients cannot tolerate certain side effects sion; fluvoxamine is approved for obsessive- and therefore may stop taking the drug. compulsive disorder. Sexual dysfunction. Although psychi- 352 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 • NUMBER 4 APRIL 2006 Downloaded from www.ccjm.org on September 23, 2021. For personal use only. All other uses require permission. atric illnesses in themselves can affect sexual TABLE 2 desire and performance, so can the drugs used to treat the illness. Sexual dysfunction is the Adverse effects of antidepressant most common side effect of all serotonin reup- drugs, based on mechanism of action take inhibitors. Delayed ejaculation, anorgas- Norepinephrine transporter blockade mia, and decreased libido can occur in up to Anxiety 60% of patients,13,14 and the effects continue Augmentation of pressor effects of sympathomimetic amines as long as the drug is taken. Diaphoresis The stimulation of serotonin 5-HT2 and Tachycardia 5-HT3 receptors is a proposed mechanism for Tremor the occurrence of sexual dysfunction due to Serotonin reuptake inhibition serotonin reuptake inhibitors, so it has been Anorexia early in the treatment and weight gain later suggested that adding medications that block Dose-dependent increase or decrease in anxiety those receptors might help with this adverse Ejaculatory disturbances, anorgasmia, and decreased libido effect. The most common medications for Extrapyramidal side effects counteracting this adverse effect fall into three Interaction with monoamine oxidase inhibitors and tryptophan groups: alpha-2 adrenergic receptor antago- Nausea, vomiting, and diarrhea. nists, serotonin 5-HT2 or 5-HT3 receptor Sedation or insomnia antagonists (eg mirtazapine), and dopaminer- Serotonin syndrome gic agents. Other strategies include decreasing Dopamine reuptake inhibition the dose; adding bupropion, sildenafil, cypro- Activation and aggravation of psychosis heptadine, or buspirone; or switching to Parkinsonism another antidepressant that has few sexual side Psychomotor activation effects, such as bupropion, mirtazapine, or Alpha-1 adrenergic receptor blockade nefazodone.2,14 Postural hypotension and dizziness Gastrointestinal effects. Sertraline and Potentiation of the antihypertensive effect of other medications fluvoxamine may cause more gastrointestinal Reflex tachycardia side effects than other serotonin reuptake Dopamine D2 receptor
Load more

Recommended publications
  • Clomipramine | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Clomipramine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Anafranil Brand Names: Canada Anafranil; MED ClomiPRAMINE; TARO-Clomipramine Warning Drugs like this one have raised the chance of suicidal thoughts or actions in children and young adults. The risk may be greater in people who have had these thoughts or actions in the past. All people who take this drug need to be watched closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur. This drug is not approved for use in all children. Talk with the doctor to be sure that this drug is right for your child. What is this drug used for? It is used to treat obsessive-compulsive problems. It may be given to you for other reasons. Talk with the doctor. Clomipramine 1/8 What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to clomipramine or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have had a recent heart attack. If you are taking any of these drugs: Linezolid or methylene blue.
    [Show full text]
  • Meta-Analysis of the Dose-Response Relationship of SSRI in Obsessive
    Molecular Psychiatry (2010) 15, 850–855 & 2010 Macmillan Publishers Limited All rights reserved 1359-4184/10 www.nature.com/mp ORIGINAL ARTICLE Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder MH Bloch1, J McGuire1, A Landeros-Weisenberger1, JF Leckman1 and C Pittenger2 1Yale Child Study Center, Yale University School of Medicine, New Haven, CT, USA and 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA We sought to determine differences in efficacy and tolerability between different doses of selective serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder (OCD) using meta-analysis. We identified 9 studies involving 2268 subjects that were randomized, double-blind placebo-controlled clinical trials that compared multiple, fixed- doses of selective serotonin reuptake inhibitors (SSRIs) to each other and to placebo in the treatment of adults with OCD. Change in Y-BOCS score, proportion of treatment responders, and dropouts (all-cause and due to side-effects) were determined for each included study. Weighted mean difference was used to examine mean change in Y-BOCS score. Pooled absolute risk difference was used to examine dichotomous outcomes. Meta-analysis was performed using a fixed effects model in RevMan 4.2.8. We found that compared with either low or medium doses, higher doses of SSRIs were associated with improved treatment efficacy, using either Y-BOCS score or proportion of treatment responders as an outcome. Dose of SSRIs was not associated with the number of all-cause dropouts. Higher doses of SSRIs were associated with significantly higher proportion of dropouts due to side-effects.
    [Show full text]
  • A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine
    A synbiotic mixture augmented the efficacy of doxepin, venlafaxine, and fluvoxamine in mice model of depression Azadeh Mesripour1, Andiya Meshkati1, Valiolah Hajhashemi2 1Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, IRAN. 2‐ Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, IRAN. ABSTRACT Objective: Currently available antidepressant drugs have notable downsides; in addition to their side effects and slow onset of action their moderate efficacy in some individuals, may influence compliance. Previous literature has shown that probiotics may have antidepressant effects. Introducing complementary medicineproof in order to augment the efficacy of therapeutic doses of antidepressant drugs seems to be very important. Therefore the effect of adding a synbiotic cocktail in drinking water was assessed in mice model of despair following administrating three antidepressant drugs belonging to different classes. Methods: The marble burring test (MBT), and forced swimming test (FST) were used as animal model of obsessive behavior and despair. The synbiotic cocktail was administered in mice drinking water (6.25×106 CFU) for 14 days and the tests were performed on the days 7 and 14 thirty minutes after injecting the lowest dose of doxepin (1 mg/kg), venlafaxine (15 mg/kg), and fluvoxamine (15 mg/kg). Results: After 7 days of the synbiotic ingestion immobility time decreased in FST for doxepin (92 sec ± 5.5) and venlafaxine (17.3 sec ± 2.5) compared to their control group (drinking water) but fluvoxamine could decrease immobility time after 14 days of ingesting the synbiotic (70 sec ± 7.5).
    [Show full text]
  • Antidepressants the Old and the New
    Antidepressants The Old and The New October, 1998 iii In 1958 researchers discovered that imipramine had antidepressant 1 activity. Since then, a number of antidepressants have been HIGHLIGHTS developed with a variety of pharmacological mechanisms and side effect profiles. All antidepressants show similar efficacy in the treatment of depression when used in adequate dosages. Choosing the most PHARMACOLOGY & CLASSIFICATION appropriate agent depends on specific patient variables, The mechanism of action for antidepressants is not entirely clear; concurrent diseases, concurrent drugs, and cost. however they are known to interfere with neurotransmitters. Non-TCA antidepressants such as the SSRIs have become Tricyclic antidepressants (TCAs) block the reuptake of both first line agents in the treatment of depression due to their norepinephrine (NE) and serotonin (5HT). The relative ratio of relative safety and tolerability. Each has its own advantages and their effect on NE versus 5HT varies. The potentiation of NE and disadvantages for consideration in individualizing therapy. 5HT results in changes in the neuroreceptors and is thought to be TCAs may be preferred in patients who do not respond to or the primary mechanism responsible for the antidepressant effect. tolerate other antidepressants, have chronic pain or migraine, or In addition to the effects on NE and 5HT, TCAs also block for whom drug cost is a significant factor. muscarinic, alpha1 adrenergic, and histaminic receptors. The extent of these effects vary with each agent resulting in differing Secondary amine TCAs (desipramine and nortriptyline) have side effect profiles. fewer side effects than tertiary amine TCAs. Maintenance therapy at full therapeutic dosages should be Selective serotonin-reuptake inhibitors (SSRIs) block the 2 considered for patients at high risk for recurrence.
    [Show full text]
  • Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice
    pharmaceuticals Article Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice Geng-Ruei Chang 1,* , Po-Hsun Hou 2,3, Wei-Cheng Yang 4, Chao-Min Wang 1 , Pei-Shan Fan 1, Huei-Jyuan Liao 1 and To-Pang Chen 5,* 1 Department of Veterinary Medicine, National Chiayi University, 580 Xinmin Road, Chiayi 60054, Taiwan; [email protected] (C.-M.W.); [email protected] (P.-S.F.); [email protected] (H.-J.L.) 2 Department of Psychiatry, Taichung Veterans General Hospital, 1650 Taiwan Boulevard (Section 4), Taichung 40705, Taiwan; [email protected] 3 Faculty of Medicine, National Yang-Ming University, 155 Linong Street (Section 2), Taipei 11221, Taiwan 4 School of Veterinary Medicine, National Taiwan University, 1 Roosevelt Road (Section 4), Taipei 10617, Taiwan; [email protected] 5 Division of Endocrinology and Metabolism, Show Chwan Memorial Hospital, 542 Chung-Shan Road (Section 1), Changhua 50008, Taiwan * Correspondence: [email protected] (G.-R.C.); [email protected] (T.-P.C.); Tel.: +886-5-2732946 (G.-R.C.); +886-4-7256166 (T.-P.C.) Abstract: Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid Citation: Chang, G.-R.; Hou, P.-H.; change, glucose homeostasis, chromium (Cr) distribution, renal impairment, liver damage, and fatty Yang, W.-C.; Wang, C.-M.; Fan, P.-S.; liver scores in C57BL6/J mice subjected to a high-fat diet and 5 mg/kg/day doxepin treatment for Liao, H.-J.; Chen, T.-P.
    [Show full text]
  • A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine
    Turk J Pharm Sci 2020;17(3):293-298 DOI: 10.4274/tjps.galenos.2019.94210 ORIGINAL ARTICLE A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine, and Fluvoxamine in a Mouse Model of Depression Sinbiyotik Karışım, Fare Depresyon Modelinde Doksepin, Venlafaksin ve Fluvoksaminin Etkinliğini Artırdı Azadeh MESRIPOUR1*, Andiya MESHKATI1, Valiollah HAJHASHEMI2 1Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Toxicology, Isfahan, Iran 2Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences, Isfahan Pharmaceutical Sciences Research Center, Isfahan, Iran ABSTRACT Objectives: Currently available antidepressant drugs have notable downsides; in addition to their side effects and slow onset of action their moderate efficacy in some individuals may influence compliance. Previous literature has shown that probiotics may have antidepressant effects. Introducing complementary medicine in order to augment the efficacy of therapeutic doses of antidepressant drugs appears to be very important. Therefore, the effect of adding a synbiotic mixture to drinking water was assessed in a mouse model of depression following the administration of three antidepressant drugs belonging to different classes. Materials and Methods: The marble burying test (MBT) and forced swimming test (FST) were used as animal models of obsessive behavior and despair. The synbiotic mixture was administered to the mice’s drinking water (6.25x106 CFU) for 14 days and the tests were performed 30 min after the injection of the lowest dose of doxepin (1 mg/kg), venlafaxine (15 mg/kg), and fluvoxamine (15 mg/kg) on days 7 and 14. Results: After 7 days of ingestion of the synbiotic mixture, immobility time decreased in the FST for doxepin (92±5.5 s) and venlafaxine (17.3±2.5 s) compared to the control group (drinking water), but fluvoxamine decreased immobility time after 14 days of ingestion of the synbiotic mixture (70±7.5 s).
    [Show full text]
  • The American Journal Of
    The American Journal of Psychiatry Residents’ Journal July 2015 Volume 10 Issue 7 Inside IN THIS ISSUE 2 New Formats and New Opportunities: The Time to Get Involved is “Now”! Rajiv Radhakrishnan, M.B.B.S., M.D. 3 Prevention of Posttraumatic Stress Disorder: Predicting Response to Trauma Jennifer H. Harris, M.D. 7 Weight Gain in Patients With Schizophrenia: A Recipe For Timely Intervention Ammar El Sara, M.B.Ch.B. 10 Hyperprolactinemia and Antipsychotics: Update for the Training Psychiatrist Stephanie Pope, M.D. 13 A Clinical Case Conference on Spiritual Growth and Healing Elizabeth S. Stevens, D.O. This issue of the Residents’ Journal features a variety of topics. Jennifer H. Har- ris, M.D., discusses prevention of posttraumatic stress disorder, with an overview 15 Priapism: A Rare but Serious of various responses to trauma. Ammar El Sara, M.B.Ch.B., presents a review of Side Effect of Trazodone clinically applicable evidence-based interventions targeting obesity in schizophre- Kamalika Roy, M.D. nia patients. Stephanie Pope, M.D., examines antipsychotic-induced hyperprolac- 17 Classifying Psychopathology: tinemia, including variables affecting prolactin and clinical implications. Elizabeth Mental Kinds and Natural Kinds S. Stevens, D.O., discusses several psychological, social, and spiritual developmen- Reviewed by Aaron J. Hauptman, tal frameworks in a clinical case conference. Kamalika Roy, M.D., presents a case M.D. of priapism as a side effect of trazodone in a middle-aged patient. Lastly, Aaron J. Hauptman, M.D., offers his review of the book Classifying Psychopathology: Mental 18 Residents’ Resources Kinds and Natural Kinds. Editor-in-Chief Associate Editors Editors Emeriti Rajiv Radhakrishnan, M.B.B.S., M.D.
    [Show full text]
  • Impact of Citalopram and Fluvoxamine on Platelet Response To
    S24_5 Impact of Citalopram and Fluvoxamine on Platelet Response to Clopidogrel, a Randomized, Double-blind, Crossover Trial Bruria Hirsh Racch1, Galia Spectre2, Ella Shai2, Amit Ritter3, David Varon2, Ronny Alcalai3 1School of Pharmacy, Hadassah Hebrew University Medical Center, Israel 2Coagulation Unit, Hematology, Hadassah Hebrew University Medical Center, Israel 3Heart Institute, Hadassah Hebrew University Medical Center, Israel Background: Selective serotonin reuptake inhibitors (SSRI) are widely used antidepressant agents. Studies have shown that use of SSRI in combination with aspirin or warfarin is associated with an increased risk bleeding, while little information is known about the interaction of SSRIs and clopidogrel. Fluvoxamine and citalopram are both SSRIs and while fluvoxamine is an inhibitor of CYP2C19 and thus might reduce the efficacy of clopidogrel, the effect of citalopram on liver metabolism is unknown. Aim: The aim was to assess the effect these two different SSRIs on platelet aggregation and on the laboratory response to clopidogrel. Methods: A randomized, double-blind, crossover study in 15 healthy volunteers comparing the antiplatelet effect of clopidogrel with and without fluvoxamine or citalopram .The response to clopidogrel was assessed by Light Transmittance Aggregometry with10µmol/L ADP and by vasodilator-stimulated phosphoprotein (VASP) phosphorylation, a measure of P2Y12 receptor reactivity. Results: Mean baseline platelet aggregation was 80.1%±3.4 and reduced to 23.5% after treatment with clopidogrel. Both fluvoxamine and citalopram had modest effect on platelet reactivity (65.8%±6.4, p=0.06 vs. baseline and 67.3%±6.3, p=0.07 vs. baseline respectively). Laboratory response to clopidogrel was significantly better in the presence of citalopram as compared to fluvoxamine both in aggregometry (23.4%±3 vs.
    [Show full text]
  • Adverse Effects of First-Line Pharmacologic Treatments of Major Depression in Older Adults
    Draft Comparative Effectiveness Review Number xx Adverse Effects of First-line Pharmacologic Treatments of Major Depression in Older Adults Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov This information is distributed solely for the purposes of predissemination peer review. It has not been formally disseminated by the Agency for Healthcare Research and Quality. The findings are subject to change based on the literature identified in the interim and peer-review/public comments and should not be referenced as definitive. It does not represent and should not be construed to represent an Agency for Healthcare Research and Quality or Department of Health and Human Services (AHRQ) determination or policy. Contract No. 290-2015-00012I Prepared by: Will be included in the final report Investigators: Will be included in the final report AHRQ Publication No. xx-EHCxxx <Month, Year> ii Purpose of the Review To assess adverse events of first-line antidepressants in the treatment of major depressive disorder in adults 65 years or older. Key Messages • Acute treatment (<12 weeks) with o Serotonin norepinephrine reuptake inhibitors (SNRIs) (duloxetine, venlafaxine), but not selective serotonin reuptake inhibitors (SSRIs) (escitalopram, fluoxetine) led to a greater number of adverse events compared with placebo. o SSRIs (citalopram, escitalopram and fluoxetine) and SNRIs (duloxetine and venlafaxine) led to a greater number of patients withdrawing from studies due to adverse events compared with placebo o Details of the contributing adverse events in RCTs were rarely reported to more clearly characterize what adverse events to expect.
    [Show full text]
  • Doxepin (Dox-E-Pin) Description: Tricyclic Antidepressant; Antihistamine Other Names for This Medication: Sinequan®, Silenor® Common Dosage Forms: Veterinary: None
    Prescription Label Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long): Prescribing Veterinarian's Name & Contact Information: Refills: [Content to be provided by prescribing veterinarian] Doxepin (dox-e-pin) Description: Tricyclic Antidepressant; Antihistamine Other Names for this Medication: Sinequan®, Silenor® Common Dosage Forms: Veterinary: None. Human: 3 mg, 6 mg, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, & 150 mg capsules; 10 mg/mL oral liquid concentrates. This information sheet does not contain all available information for this medication. It is to help answer commonly asked questions and help you give the medication safely and effectively to your animal. If you have other questions or need more information about this medication, contact your veterinarian or pharmacist. Key Information When used as an antihistamine, doxepin should be used on a regular, ongoing basis in animals that respond to it. This drug works better if used before exposure to an allergen (eg, pollens). When used for behavior modification, it may take several days to weeks to determine if doxepin is effective. May be given with or without food. If your animal vomits or acts sick after receiving the drug on an empty stomach, try giving the next dose with food or a small treat. If vomiting continues, contact your veterinarian. Most common side effects are sleepiness, dry mouth, and constipation. Be sure your animal always has access to plenty of fresh, clean water. Rare side effects that can be serious (contact veterinarian immediately) include abnormal bleeding, lack of an appetite, seizures, collapse, or profound sleepiness.
    [Show full text]
  • Diagnosis and Management of Post-Traumatic Stress Disorder BRADLEY D
    Diagnosis and Management of Post-traumatic Stress Disorder BRADLEY D. GRINAGE, M.D., University of Kansas School of Medicine–Wichita, Wichita, Kansas Although post-traumatic stress disorder (PTSD) is a debilitating anxiety disorder that may cause significant distress and increased use of health resources, the condition O A patient informa- often goes undiagnosed. The lifetime prevalence of PTSD in the United States is 8 to tion handout on post- traumatic stress disor- 9 percent, and approximately 25 to 30 percent of victims of significant trauma der, written by the develop PTSD. The emotional and physical symptoms of PTSD occur in three clusters: author of this article, re-experiencing the trauma, marked avoidance of usual activities, and increased is provided on page symptoms of arousal. Before a diagnosis of PTSD can be made, the patient’s symp- 2409. toms must significantly disrupt normal activities and last for more than one month. Approximately 80 percent of patients with PTSD have at least one comorbid psychi- atric disorder. The most common comorbid disorders include depression, alcohol and drug abuse, and other anxiety disorders. Treatment relies on a multidimensional approach, including supportive patient education, cognitive behavior therapy, and psychopharmacology. Selective serotonin reuptake inhibitors are the mainstay of pharmacologic treatment. (Am Fam Physician 2003;68:2401-8,2409. Copyright© 2003 American Academy of Family Physicians) ost-traumatic stress disorder Background (PTSD) is an anxiety disorder The psychologic effects of trauma have that occurs following exposure to been described throughout military history. a traumatic event. The disorder Da Costa syndrome (“soldier’s heart”), which has not been extensively studied is characterized by cardiac symptoms associ- Pin primary care; however, the events of Sep- ated with irritability and increased arousal, tember 11, 2001, raised both public and pro- was described in veterans of the American fessional awareness of PTSD.
    [Show full text]
  • Pharmacotherapy of Post-Traumatic Stress Disorder: Going Beyond the Guidelines Jonathan Davidson
    BJPsych Open (2016) 2, e16–e18. doi: 10.1192/bjpo.bp.116.003707 Editorial Pharmacotherapy of post-traumatic stress disorder: going beyond the guidelines Jonathan Davidson Summary royalties in connection with publications by Springer, Guilford This article discusses the study of Harpaz-Rotem and associates, and McFarland Publishers and use of the Connor-Davidson who examined patterns of medication use in first-diagnosed Resilience Scale, Davidson Trauma Scale, Social Phobia veterans with post-traumatic stress disorder (PTSD). It considers Inventory (SPIN) and Mini-SPIN; service on the INTRuST Data the difference between practice guidelines and actual Safety and Monitoring Board, University of California, San prescribing; selectively identifies issues with antidepressants, Diego. antipsychotics, benzodiazepines and prazosin; and reviews the possible impact of new medications in the pipeline. Copyright and usage © The Royal College of Psychiatrists 2016. This is an open Declaration of interests access article distributed under the terms of the Creative In the past 36 months, J.D. has received compensation for Commons Non-Commercial, No Derivatives (CC BY-NC-ND) consulting with Edgemont, Turing and Tonix Pharmaceuticals; license. For some decades, there has been steady progress in the treatment Each drug group will be considered in turn, the matter of of post-traumatic stress reactions. The growth of evidence-based polypharmacy will be discussed, and concluding remarks will medicine over the past 20 years has placed a premium on ran‐ sketch out five ways in which pharmacotherapy advances might domised controlled trials (RCTs), which are typically based on impact the treatment of PTSD. samples that do not represent real-world clinical practice.
    [Show full text]